Updated:
Zura Bio
Zura Bio builds a pipeline of clinical-stage immunology assets through licensing, led by CEO Someit Sidhu.
Zura Bio
Zura Bio was formed in 2021 by CEO Someit Sidhu to formalize a disciplined model for acquiring legacy immunology assets. The firm targets therapies that have already generated human proof-of-concept data but were deprioritized by larger pharma companies. Its first major move — acquiring a portfolio of clinical-stage antibodies from a large pharmaceutical firm — signaled a commitment to licensing as the primary source of pipeline generation. Zura Bio focuses exclusively on immunology, with programs crossing the translational gap into clinical development. Confirmed programs include ZB-001, an antibody targeting inflammatory pathways, and additional undisclosed assets with data supporting application in systemic sclerosis and other rheumatologic conditions. The firm operates a lean structure, conducting clinical development through outsourced CRO networks rather than building internal lab infrastructure. Its geographic footprint centers on clinical trial sites in the United Kingdom and Eastern Europe. As of mid-2023, Zura Bio expanded its balance sheet through a de-SPAC transaction, listing publicly to fund ongoing trials and additional asset licensing. The firm has not disclosed total deployment or headcount. Kiran Nandra is Chief Scientific Officer, with prior experience in immunology research at several private biotech firms. Zura Bio’s design differs from conventional biotech startups. Rather than funding early-stage science, the firm functions as a vehicle for financing clinical-stage immunology programs that existing pharma owners cannot prioritize. This structure reduces scientific risk while transferring development execution to a team dedicated to single-asset progress — a model that narrows the gap between licensing and potential regulatory submission.
General information
Firm type
Asset Manager
Year founded
2021
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
Someit Sidhu
Chief Executive Officer
Verender Badial
Chief Financial Officer
Kiran Nandra
Chief Scientific Officer
Sector focus
Frequently asked questions
What investment stages does Zura Bio typically target?
Zura Bio in-licenses clinical-stage therapeutic candidates, typically at Phase 1b or Phase 2a, when human proof-of-concept data exists but the originating pharma company elected not to prioritize the program. The firm does not fund pre-clinical discovery. This places capital at the point of translational validation, reducing binary risk while retaining development upside.
How does Zura Bio source its therapeutic pipeline?
The firm sources exclusively through M&A and licensing agreements with large pharmaceutical companies. Zura Bio identifies deprioritized immunology assets — programs that produced positive early clinical signals but were sidelined due to portfolio reprioritization — and acquires global or regional development rights. It does not conduct internal drug discovery or operate wet-lab facilities.
Is Zura Bio structured as a family office or does it operate more like a biotech company?
Zura Bio is a publicly traded clinical-stage biotech company formed through a special-purpose acquisition company (SPAC) in 2023. It is not a family office. Its strategy mirrors a therapeutic-focused asset manager — acquiring programs, financing development, and aiming for regulatory submission — rather than a traditional diversified investment vehicle.
What therapeutic areas does Zura Bio focus on?
Zura Bio concentrates on immunology and autoimmune diseases. Confirmed areas of interest include systemic sclerosis, rheumatoid arthritis, and other rheumatologic or inflammatory conditions where clinical antibodies have shown target engagement. The firm has not publicly indicated interest in oncology, neuroscience, or rare metabolic disorders.
Who leads clinical development decisions at Zura Bio?
Kiran Nandra serves as Chief Scientific Officer and leads clinical strategy and translational development. CEO Someit Sidhu oversees corporate strategy and capital allocation. The firm operates a flat structure, with program teams relying on external CROs and academic investigators to execute trials.
Does Zura Bio participate in fund commitments or only direct programs?
Zura Bio does not operate as a venture capital fund. It invests directly in therapeutic programs by acquiring IP and funding clinical development. The firm has no publicly disclosed fund-of-funds activity secondary investments, or LP commitments to external venture funds.
What is Zura Bio's known posture on partnerships with other biotech firms?
Zura Bio enters partnerships as licensee, not as partner. It acquires development-stage assets and funds clinical execution independently, using outsourced service providers. The firm has not announced co-development or joint-venture structures with other biotech firms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: